Drug intelligence / Profile preview

BAY2328065

Development stage: Phase 1
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral

Overview

BAY2328065 is an investigational small molecule drug developed by Bayer for the treatment of endometriosis. It is being evaluated in oral tablet and solution formulations. The drug acts as an antagonist of purinergic receptors, specifically targeting P2X4 and possibly P2X3 receptors, which are thought to play a role in pain and inflammation associated with endometriosis. Clinical studies have focused on its safety, tolerability, pharmacokinetics, and bioavailability in healthy volunteers as well as its potential to block proteins involved in pain and swelling of tissue relevant to endometriosis[1][2][3][4][5].

Targets

P2RX4 (P2X Purinoceptor 4)

Beyond the preview

Go deeper on BAY2328065.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAY2328065.

Explore the full profile